Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imidazolyl ethanamide pentandioic acid - Valenta Pharmaceuticals

Next Previous
Drug Profile

Imidazolyl ethanamide pentandioic acid - Valenta Pharmaceuticals

Alternative Names: Ingavirin; Myelo 001; Vitaglutam

Latest Information Update: 06 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valenta Pharmaceuticals
  • Developer Myelo Therapeutics; Valenta Pharmaceuticals
  • Class Antivirals; Imidazoles; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections; Neutropenia; Viral infections
  • Phase III COVID 2019 infections
  • No development reported Acute radiation syndrome; Myelosuppression

Most Recent Events

  • 06 Feb 2026 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) is underway in Russia (PO) (NCT05216497)
  • 06 Feb 2026 Launched for Influenza virus infections (In infants) in Russia (PO), prior to February 2026 (Valenta Pharmaceuticals website, February 2026)
  • 06 Feb 2026 Launched for Viral infections (In adolescents) in Russia (PO), prior to February 2026 (Valenta Pharmaceuticals website, February 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top